文献速递瓣膜病与结构性心脏病血脂与心血管预防

TAVR术中脑栓塞保护装置降低围术期卒中率:患者水平倾向匹配分析

Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis.
PubMed 文献 · Eur Heart J · 2019-01-01

该研究将SENTINEL US IDE试验与CLEAN-TAVI、SENTINEL-Ulm研究进行患者水平汇总分析(N=1306),经倾向评分匹配后比较533例无脑栓塞保护(CEP)与533例使用双滤器CEP装置的TAVR患者。结果显示CEP组围术期全因卒中显著降低(1.88% vs 5.44%,OR 0.35,95%CI 0.17-0.72,P=0.0028),全因死亡或全因卒中复合终点亦显著降低(2.06% vs 6.00%,OR 0.34,95%CI 0.17-0.68,P=0.0013);作者指出仍需随机试验进一步明确。

要点

  • 双滤器CEP装置与TAVR术后72小时内全因卒中风险显著降低相关(OR 0.35)。
  • CEP组全因死亡或全因卒中复合终点亦显著低于无保护组(OR 0.34)。
  • 结论为关联性,随机试验仍需验证CEP对卒中率的确定性影响。

核心结论

  • 使用双滤器CEP装置的TAVR患者围术期卒中率显著低于无保护TAVR患者,但随机试验仍需明确该问题。

研究设计与样本

  • 患者水平汇总分析,合并SENTINEL US IDE试验、CLEAN-TAVI与SENTINEL-Ulm研究,总样本N=1306。
  • 采用倾向评分匹配调整混杂因素,匹配后无CEP组533例、CEP组533例。
  • 主要终点为TAVR术后72小时内按VARC-2标准判定的操作性卒中;次要终点为术后72小时内全因死亡或全因卒中复合终点。

主要发现

  • 匹配人群中,无CEP组与CEP组基线特征、手术入路及瓣膜类型相似。
  • CEP组操作性全因卒中为1.88%,无CEP组为5.44%,OR 0.35(95%CI 0.17-0.72),相对风险降低65%,P=0.0028。
  • CEP组全因死亡或全因卒中复合终点为2.06%,无CEP组为6.00%,OR 0.34(95%CI 0.17-0.68),相对风险降低66%,P=0.0013。

临床怎么用

  • 在TAVR术中可考虑使用双滤器CEP装置以降低围术期卒中风险,但需结合患者个体情况与证据不确定性综合决策。

局限性

  • 为患者水平汇总分析而非随机对照试验,作者指出仍需随机试验澄清CEP对TAVR围术期卒中的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The role of cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR) remains controversial. Randomized trials have not been powered to demonstrate a reduction in stroke rates. The aim of this patient level pooled analysis was to validate the impact of the dual-filter CEP device (Claret Medical Inc., CA, USA) on peri-procedural stroke in a large number of TAVR patients. METHODS AND RESULTS: Patients from the SENTINEL US IDE trial were combined with the CLEAN-TAVI and SENTINEL-Ulm study in a patient level pooled analysis (N = 1306). Propensity score matching was performed to adjust for possible confounders. The primary endpoint was procedural stroke within 72 h post-TAVR according to Valve Academic Research Consortium-2 criteria. The secondary endpoint was the combination of all-cause mortality or all-stroke within 72 h after TAVR. In the propensity-matched population, 533 patients underwent TAVR without CEP and 533 patients underwent TAVR with CEP. TAVR patients without vs. with CEP were similar with respect to baseline characteristics, procedural approach, or valve type. In patients undergoing TAVR with dual-filter CEP, procedural all-stroke was significantly lower compared with unprotected procedures [1.88% vs. 5.44%, odds ratio 0.35, 95% confidence interval (CI) 0.17-0.72, relative risk reduction 65%, P = 0.0028]. In addition, all-cause mortality and all-stroke were significantly lower (2.06% vs. 6.00%, odds ratio 0.34, 95% CI 0.17-0.68, relative risk reduction 66%, P = 0.0013). CONCLUSION: Our findings suggest that TAVR with the dual-filter CEP device is associated with a significant lower rate of peri-procedural stroke compared with unprotected procedures. However, randomized trials are still needed to clarify this issue.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Seeger J, Kapadia SR, Kodali S, et al. Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. Eur Heart J. 2019. PMID: 30590554. doi:10.1093/eurheartj/ehy847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。